Cargando…

The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist and a Potent Antagonist to Test the Standardized Protocol

The Organisation for Economic Cooperation and Development (OECD) has completed phase 1 of the Hershberger validation intended to identify in vivo activity of suspected androgens and anti-androgens. Seventeen laboratories from 7 countries participated in phase 1, and results were collated and evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Owens, William, Zeiger, Errol, Walker, Michael, Ashby, John, Onyon, Lesley, Gray, L. Earl
Formato: Texto
Lenguaje:English
Publicado: National Institute of Environmental Health Sciences 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1552005/
https://www.ncbi.nlm.nih.gov/pubmed/16882536
http://dx.doi.org/10.1289/ehp.8751
_version_ 1782129326958837760
author Owens, William
Zeiger, Errol
Walker, Michael
Ashby, John
Onyon, Lesley
Gray, L. Earl
author_facet Owens, William
Zeiger, Errol
Walker, Michael
Ashby, John
Onyon, Lesley
Gray, L. Earl
author_sort Owens, William
collection PubMed
description The Organisation for Economic Cooperation and Development (OECD) has completed phase 1 of the Hershberger validation intended to identify in vivo activity of suspected androgens and anti-androgens. Seventeen laboratories from 7 countries participated in phase 1, and results were collated and evaluated by the OECD with the support of an international committee of experts. Five androgen-responsive tissues (ventral prostate, paired seminal vesicles and coagulating glands, levator ani and bulbocavernosus muscles, glans penis, and paired Cowper’s or bulbourethral glands) were evaluated. The standardized protocols used selected doses of a reference androgen, testosterone propionate (TP), and an antiandrogen, flutamide (FLU). All laboratories successfully detected TP-stimulated increases in androgen-responsive tissue weight and decreases in TP-stimulated tissue weights when FLU was co-administered. The standardized protocols performed well under a variety of conditions (e.g., strain, diet, housing protocol, bedding). There was good agreement among laboratories with regard to the TP doses inducing significant increases in tissue weights and the FLU doses decreasing TP-stimulated tissue weights. Several additional procedures (e.g., weighing of the dorsolateral prostate and fixation of tissues before weighing) and serum component measurements (e.g., luteinizing hormone) were also included by some laboratories to assess their potential utility. The results indicated that the OECD Hershberger protocol was robust, reproducible, and transferable across laboratories. Based on this phase 1 validation study, the protocols have been refined, and the next phase of the OECD validation program will test the protocol with selected doses of weak androgen agonists, androgen antagonists, a 5α-reductase inhibitor, and chemicals having no androgenic activity.
format Text
id pubmed-1552005
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher National Institute of Environmental Health Sciences
record_format MEDLINE/PubMed
spelling pubmed-15520052006-08-29 The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist and a Potent Antagonist to Test the Standardized Protocol Owens, William Zeiger, Errol Walker, Michael Ashby, John Onyon, Lesley Gray, L. Earl Environ Health Perspect Research The Organisation for Economic Cooperation and Development (OECD) has completed phase 1 of the Hershberger validation intended to identify in vivo activity of suspected androgens and anti-androgens. Seventeen laboratories from 7 countries participated in phase 1, and results were collated and evaluated by the OECD with the support of an international committee of experts. Five androgen-responsive tissues (ventral prostate, paired seminal vesicles and coagulating glands, levator ani and bulbocavernosus muscles, glans penis, and paired Cowper’s or bulbourethral glands) were evaluated. The standardized protocols used selected doses of a reference androgen, testosterone propionate (TP), and an antiandrogen, flutamide (FLU). All laboratories successfully detected TP-stimulated increases in androgen-responsive tissue weight and decreases in TP-stimulated tissue weights when FLU was co-administered. The standardized protocols performed well under a variety of conditions (e.g., strain, diet, housing protocol, bedding). There was good agreement among laboratories with regard to the TP doses inducing significant increases in tissue weights and the FLU doses decreasing TP-stimulated tissue weights. Several additional procedures (e.g., weighing of the dorsolateral prostate and fixation of tissues before weighing) and serum component measurements (e.g., luteinizing hormone) were also included by some laboratories to assess their potential utility. The results indicated that the OECD Hershberger protocol was robust, reproducible, and transferable across laboratories. Based on this phase 1 validation study, the protocols have been refined, and the next phase of the OECD validation program will test the protocol with selected doses of weak androgen agonists, androgen antagonists, a 5α-reductase inhibitor, and chemicals having no androgenic activity. National Institute of Environmental Health Sciences 2006-08 2006-02-27 /pmc/articles/PMC1552005/ /pubmed/16882536 http://dx.doi.org/10.1289/ehp.8751 Text en http://creativecommons.org/publicdomain/mark/1.0/ Publication of EHP lies in the public domain and is therefore without copyright. All text from EHP may be reprinted freely. Use of materials published in EHP should be acknowledged (for example, ?Reproduced with permission from Environmental Health Perspectives?); pertinent reference information should be provided for the article from which the material was reproduced. Articles from EHP, especially the News section, may contain photographs or illustrations copyrighted by other commercial organizations or individuals that may not be used without obtaining prior approval from the holder of the copyright.
spellingShingle Research
Owens, William
Zeiger, Errol
Walker, Michael
Ashby, John
Onyon, Lesley
Gray, L. Earl
The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist and a Potent Antagonist to Test the Standardized Protocol
title The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist and a Potent Antagonist to Test the Standardized Protocol
title_full The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist and a Potent Antagonist to Test the Standardized Protocol
title_fullStr The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist and a Potent Antagonist to Test the Standardized Protocol
title_full_unstemmed The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist and a Potent Antagonist to Test the Standardized Protocol
title_short The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonist and a Potent Antagonist to Test the Standardized Protocol
title_sort oecd program to validate the rat hershberger bioassay to screen compounds for in vivo androgen and antiandrogen responses. phase 1: use of a potent agonist and a potent antagonist to test the standardized protocol
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1552005/
https://www.ncbi.nlm.nih.gov/pubmed/16882536
http://dx.doi.org/10.1289/ehp.8751
work_keys_str_mv AT owenswilliam theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol
AT zeigererrol theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol
AT walkermichael theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol
AT ashbyjohn theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol
AT onyonlesley theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol
AT graylearl theoecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol
AT owenswilliam oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol
AT zeigererrol oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol
AT walkermichael oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol
AT ashbyjohn oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol
AT onyonlesley oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol
AT graylearl oecdprogramtovalidatetherathershbergerbioassaytoscreencompoundsforinvivoandrogenandantiandrogenresponsesphase1useofapotentagonistandapotentantagonisttotestthestandardizedprotocol